A Phase 2 interventional study of EDP-938 Dose 1 and EDP-938 Dose 2 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-03.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 4 in phase 2, and was the 2nd registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Enanta Pharmaceuticals, Inc · Sites in Thailand
Ages 28 days–36 mo
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 179 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 81 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 2, and was the 2nd registered.
Enanta Pharmaceuticals, Inc’s Respiratory Syncytial Virus Infections studies by the year they started, since 2017.
1 of the studies testing EDP-938 in Respiratory Syncytial Virus Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482657Enanta Pharmaceuticals, IncA Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Enanta Pharmaceuticals, Inc’s 14 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take EDP-938 Dose 1 oral suspension for 5 days
Drug: EDP-938 Dose 1
Subjects will take EDP-938 Dose 2 oral suspension for 5 days
Drug: EDP-938 Dose 2
Subjects will take matching placebo oral suspension for 5 days
Drug: Placebo
Subjects will take EDP-938 Dose 3 oral suspension for 5 days
Drug: EDP-938 Dose 3
Subjects will take EDP-938 Dose 4 oral suspension for 5 days
Drug: EDP-938 Dose 4
Subjects will take matching placebo oral suspension for 5 days
Drug: Placebo
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load
Measured in nasal washes by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in participants inoculated with respiratory syncytial virus-A (RSV-A) Memphis 37b.
Time frame: Twice daily on Day 2 through Day 11 and once on Day 12
Area Under the Curve (AUC) of Total Symptom Score
Total symptom scores (from the 10-item Diary Card) were used to calculate the AUC. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). Data presented is hours x score.
Time frame: Three times daily on Day 0 to Day 11, once on Day 12
Peak Total Symptom Score
Peak total symptom score was defined as the highest total symptom score between first dose of study drug and Day 12. Values presented are a sum of individual symptom scores, with a potential range of 0 (best) to 30 (worst). Total symptom scores at the time of the first dose of study drug can be before or after dosing. Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness
Time frame: Day 2 to Day 12
Total Symptom Score
Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities. Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness
Time frame: Day 2 to Day 9
Time to Peak Total Symptom Score
Time to peak total symptom score was defined as the time in days to the highest total symptom score between first dose of study drug and Day 12. Total symptom scores at the time of the first dose of study drug can be before or after dosing.
Time frame: Day 2 to Day 12
Time to Resolution From Peak Total Symptom Score
Time to resolution from peak total symptom score was defined as the time in days from the highest total symptom score (between first dose of study drug and Day 12) until the start of the first 24-hour symptom-free period (after the highest total symptom score). Total symptom scores at the time of the first dose of study drug can be before or after dosing.
Time frame: Day 2 to Day 12
Total Weight of Nasal Mucus Produced
Measured via weighed paper tissues and reported as a mean total across all study days.
Time frame: Day 2 to Day 12
Peak Viral Load
Peak viral load was defined as the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.
Time frame: Day 2 to Day 12
Time to Peak Viral Load
Time to peak viral load was defined as the time to the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.
Time frame: Day 2 to Day 12
Time to Resolution From Peak Viral Load
Time to resolution from peak viral load was defined as the time from peak until first confirmed undetectable assessment between first dose of study drug and Day 12. Measured by by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).
Time frame: Day 2 to Day 12
Time to Cessation of Virus Detection
Time to cessation of virus detection was measured by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).
Time frame: Day 2 to Day 12
Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant physical examinations, vital signs, clinical laboratory tests (including biochemistry, hematology, coagulation \[if required\], cardiac enzymes and urine analysis), 12-lead electrocardiograms (ECGs) and spirometry results were recorded as adverse events.
Time frame: Day 2 to Day 28
Maximum Plasma Concentration (Cmax) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Terminal Phase Half-Life (t1/2) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Apparent Systemic Clearance at Steady State (CLss/F) of EDP-938
Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Terminal Phase Rate Constant Calculated by Linear Regression of the Terminal Loglinear Portion of the Concentration vs. Time Curve (λz) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Volume of Distribution at Steady State (Vss/F) of EDP-938
Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Plasma Concentration at 12 Hours (C12) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2 and Day 7; 12 hours post-dose
Plasma Concentration at 24 Hours (C24) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2 and Day 7; 24 hours post-dose
Area Under the Concentration Time Curve Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2: pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours post-dose; and Day 7: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of EDP-938 and Its Metabolites
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
Time frame: Day 2 and Day 6: Pre-dose, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-dose; Day 7 only: 15, 24, 30, 36, 48, 60, and 72 hours post-dose
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC
The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable viral load AUC i.e. a low PK AUC and a high viral load AUC indicated a correlation.
Time frame: Day 2 to Day 18
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC
The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable TSS AUC, i.e. a low PK AUC and a high TSS AUC indicated a correlation.
Time frame: Day 2 to Day 18
A total of 179 participants enrolled in the trial at one site in the United Kingdom from October 2018 to October 2019.
| Milestone | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 39 | 38 | 38 | 21 | 21 | 21 |
| Inoculated with challenge virus | 39 | 38 | 38 | 21 | 21 | 21 |
| Received treatment | 38 | 38 | 38 | 21 | 21 | 21 |
| Completed | 39 | 38 | 38 | 21 | 21 | 21 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Measured in nasal washes by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in participants inoculated with respiratory syncytial virus-A (RSV-A) Memphis 37b.
| hours*log10 copies/milliliter (mL) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load | 134.70 ± 85.1 | 113.51 ± 99.9 | 624.30 ± 51.7 | 80.61 ± 112.1 | 160.81 ± 63.3 | 808.28 ± 37.1 |
Total symptom scores (from the 10-item Diary Card) were used to calculate the AUC. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). Data presented is hours x score.
| hours*score | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Area Under the Curve (AUC) of Total Symptom Score | 61.18 ± 347.8 | 37.36 ± 1640.1 | 252.49 ± 243.9 | 26.70 ± 730.2 | 27.81 ± 436.8 | 232.53 ± 530.9 |
Peak total symptom score was defined as the highest total symptom score between first dose of study drug and Day 12. Values presented are a sum of individual symptom scores, with a potential range of 0 (best) to 30 (worst). Total symptom scores at the time of the first dose of study drug can be before or after dosing. Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities: * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness
| Scores on a scale | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Peak Total Symptom Score | 2.3 ± 53.9 | 1.9 ± 89.8 | 4.9 ± 77.9 | 1.6 ± 68.5 | 1.8 ± 55.6 | 4.2 ± 85.8 |
Measured by the 10-item Diary Card. Each individual symptom score was graded on a scale of 0-3, where Grade 0 is absence, Grade 1 is just noticeable, Grade 2 is bothersome but does not prevent participation in activities and Grade 3 is bothersome and interferes with activities. Total symptom score is the sum of individual symptom scores with a potential range of 0 (best) to 30 (worst). * Runny nose * Stuffy nose * Sneezing * Sore throat * Earache * Malaise (Tiredness) * Cough * Shortness of breath * Headache * Muscle/ joint ache/ stiffness
| Scores on a scale | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Relative Day 2 Assessment 1 | 0.9 ± 97.5 | 0.8 ± 155.4 | 1.9 ± 117.0 | 0.5 ± 140.8 | 0.3 ± 222.5 | 3.0 ± 66.6 |
| Relative Day 2 Assessment 2 | 0.8 ± 94.0 | 0.7 ± 160.3 | 2.4 ± 110.3 | 0.4 ± 185.2 | 0.5 ± 179.8 | 2.9 ± 82.5 |
| Relative Day 2 Assessment 3 | 0.5 ± 117.0 | 0.6 ± 184.4 | 2.7 ± 94.9 | 0.3 ± 196.2 | 0.2 ± 331.7 | 2.6 ± 94.3 |
| Relative Day 3 Assessment 1 | 0.4 ± 137.3 | 0.7 ± 148.5 | 2.6 ± 99.1 | 0.4 ± 166.9 | 0.2 ± 254.2 | 2.2 ± 103.0 |
| Relative Day 3 Assessment 2 | 0.4 ± 144.3 | 0.6 ± 175.2 | 2.7 ± 90.5 | 0.3 ± 207.0 | 0.3 ± 237.1 | 2.3 ± 101.0 |
| Relative Day 3 Assessment 3 | 0.3 ± 190.9 | 0.6 ± 167.7 | 2.5 ± 103.7 | 0.2 ± 332.6 | 0.3 ± 276.4 | 2.2 ± 95.3 |
| Relative Day 4 Assessment 1 | 0.3 ± 177.1 | 0.5 ± 154.9 | 2.3 ± 103.8 | 0.2 ± 343.9 | 0.2 ± 254.2 | 1.9 ± 92.6 |
| Relative Day 4 Assessment 2 | 0.3 ± 186.5 | 0.6 ± 163.1 | 1.8 ± 115.3 | 0.1 ± 387.3 | 0.1 ± 331.7 | 1.7 ± 85.0 |
| Relative Day 4 Assessment 3 | 0.3 ± 263.0 | 0.4 ± 163.5 | 1.8 ± 103.1 | 0.2 ± 280.3 | 0.1 ± 331.7 | 1.8 ± 88.3 |
| Relative Day 5 Assessment 1 | 0.2 ± 228.2 | 0.5 ± 158.9 | 1.6 ± 108.3 | 0.2 ± 244.9 | 0.2 ± 254.2 | 1.6 ± 87.9 |
| Relative Day 5 Assessment 2 | 0.3 ± 191.3 | 0.4 ± 177.1 | 1.4 ± 109.2 | 0.2 ± 314.0 | 0.2 ± 254.2 | 1.4 ± 112.8 |
| Relative Day 5 Assessment 3 | 0.1 ± 364.8 | 0.4 ± 162.0 | 1.3 ± 115.9 | 0.1 ± 280.3 | 0.1 ± 331.7 | 1.4 ± 89.6 |
| Relative Day 6 Assessment 1 | 0.2 ± 300.9 | 0.4 ± 186.9 | 1.2 ± 106.0 | 0.2 ± 314.0 | 0.2 ± 237.1 | 1.5 ± 83.3 |
| Relative Day 6 Assessment 2 | 0.2 ± 288.7 | 0.4 ± 186.9 | 1.0 ± 112.8 | 0.1 ± 387.3 | 0.3 ± 185.4 | 1.2 ± 102.4 |
| Relative Day 6 Assessment 3 | 0.2 ± 280.9 | 0.3 ± 184.6 | 1.0 ± 100.5 | 0.1 ± 387.3 | 0.1 ± 210.8 | 1.1 ± 116.5 |
| Relative Day 7 Assessment 1 | 0.2 ± 225.1 | 0.2 ± 205.3 | 0.7 ± 124.9 | 0.1 ± 387.3 | 0.1 ± 316.2 | 0.8 ± 126.1 |
| Relative Day 7 Assessment 2 | 0.2 ± 196.2 | 0.2 ± 162.0 | 0.7 ± 115.7 | 0.1 ± 346.4 | 0.1 ± 300.0 | 0.9 ± 153.5 |
| Relative Day 7 Assessment 3 | 0.2 ± 291.0 | 0.2 ± 185.8 | 0.9 ± 89.9 | 0.1 ± 331.7 | 0.0 ± NA | 0.7 ± 179.2 |
| Relative Day 8 Assessment 1 | 0.1 ± 291.0 | 0.2 ± 199.9 | 0.9 ± 94.9 | 0.1 ± 331.7 | 0.0 ± NA | 0.5 ± 153.7 |
| Relative Day 8 Assessment 2 | 0.1 ± 374.2 | 0.1 ± 244.1 | 0.9 ± 99.4 | 0.2 ± 264.6 | 0.0 ± NA | 0.2 ± 170.8 |
| Relative Day 8 Assessment 3 | 0.0 ± NA | 0.4 ± 149.1 | 0.6 ± 129.1 | 0.0 ± NA | — | 0.2 ± 200.0 |
| Relative Day 9 Assessment 1 | 0.0 ± NA | 0.0 ± NA | 0.4 ± 140.5 | 0.0 ± NA | — | 0.2 ± 200.0 |
| Relative Day 9 Assessment 2 | 0.0 ± NA | 0.0 ± NA | 0.5 ± 91.3 | 0.0 ± NA | — | 0.4 ± 141.4 |
Time to peak total symptom score was defined as the time in days to the highest total symptom score between first dose of study drug and Day 12. Total symptom scores at the time of the first dose of study drug can be before or after dosing.
| Days | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Peak Total Symptom Score | 1.18 ± 137.8 | 1.76 ± 110.0 | 2.15 ± 71.4 | 1.45 ± 131.9 | 1.09 ± 136.4 | 1.94 ± 80.5 |
Time to resolution from peak total symptom score was defined as the time in days from the highest total symptom score (between first dose of study drug and Day 12) until the start of the first 24-hour symptom-free period (after the highest total symptom score). Total symptom scores at the time of the first dose of study drug can be before or after dosing.
| Days | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Resolution From Peak Total Symptom Score | 2.49 ± 70.1 | 2.83 ± 77.5 | 3.30 ± 61.7 | 2.19 ± 70.0 | 1.38 ± 116.5 | 5.17 ± 383 |
Measured via weighed paper tissues and reported as a mean total across all study days.
| Grams | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Total Weight of Nasal Mucus Produced | 12.965 ± 13.0314 | 7.428 ± 11.1324 | 33.416 ± 37.8072 | 2.983 ± 4.4226 | 4.716 ± 6.0015 | 22.391 ± 20.6005 |
Peak viral load was defined as the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.
| log10 copies/milliliter (mL) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Peak Viral Load | 4.3552 ± 1.56334 | 4.3111 ± 1.76974 | 6.4727 ± 1.60659 | 3.9718 ± 1.78873 | 4.7727 ± 1.35014 | 7.0973 ± 1.24388 |
Time to peak viral load was defined as the time to the highest quantitative reverse transcription polymerase chain reaction (RT-qPCR) viral load value between first dose of study drug and Day 12. Measured by nasal wash RT-qPCR.
| Days | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Peak Viral Load | 0.74 ± 75.6 | 0.80 ± 130.2 | 2.59 ± 48.5 | 0.88 ± 181.3 | 0.79 ± 64.0 | 3.43 ± 33.7 |
Time to resolution from peak viral load was defined as the time from peak until first confirmed undetectable assessment between first dose of study drug and Day 12. Measured by by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).
| Days | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Resolution From Peak Viral Load | 2.03 ± 72.1 | 2.02 ± 79.7 | 4.03 ± 47.5 | 1.67 ± 77.1 | 1.63 ± 43.7 | 3.58 ± 45.6 |
Time to cessation of virus detection was measured by nasal wash quantitative reverse transcription polymerase chain reaction (RT-qPCR).
| Days | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Time to Cessation of Virus Detection | 3.5 (2.0 to 4.5) | 3.2 (1.5 to 4.5) | 8.5 (6.5 to NA) | 2.7 (1.5 to 4.0) | 2.5 (1.5 to 3.5) | 8.5 (7.0 to 9.0) |
A TEAE was defined as any untoward medical occurrence in participants that happened after study drug administration. Any clinically significant physical examinations, vital signs, clinical laboratory tests (including biochemistry, hematology, coagulation \[if required\], cardiac enzymes and urine analysis), 12-lead electrocardiograms (ECGs) and spirometry results were recorded as adverse events.
| Participants | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 20 | 21 | 21 | 8 | 10 | 11 |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| nanograms per milliliter (ng/mL) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 First Dose | 1370 ± 49.7 | 1151 ± 46.9 | 1237.91 ± 33.2 | 800.73 ± 44.9 |
| EDP-938 Last Dose | 1740 ± 52.8 | 1480 ± 33.4 | 1010 ± 15.9 | 901 ± 27.9 |
| EP-024636 First Dose | 256 ± 39.3 | 215 ± 41.3 | 264 ± 42.0 | 177 ± 48.2 |
| EP-024636 Last Dose | 361 ± 34.8 | 342 ± 27.8 | 230 ± 23.0 | 232 ± 32.0 |
| EP-024594 First Dose | 96.3 ± 48.1 | 76.8 ± 54.8 | 102 ± 61.1 | 72.3 ± 49.1 |
| EP-024594 Last Dose | 203 ± 32.6 | 240 ± 30.1 | 130 ± 44.1 | 168 ± 32.9 |
| EP-024595 First Dose | 150 ± 63.2 | 102 ± 79.6 | 167 ± 81.1 | 100 ± 72.1 |
| EP-024595 Last Dose | 717 ± 45.6 | 1000 ± 49.1 | 499 ± 89.0 | 692 ± 50.5 |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| Hours | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 First Dose | 4.56 (2.0 to 10.0) | 5.00 (1.0 to 12.0) | 5.80 (1.9 to 10.2) | 6.07 (2.0 to 10.2) |
| EDP-938 Last Dose | 4.52 (1.9 to 17.0) | 4.10 (0.0 to 10.1) | 4.98 (1.0 to 15.9) | 4.04 (0.0 to 10.0) |
| EP-024636 First Dose | 5.91 (2.9 to 23.5) | 5.97 (2.0 to 12.0) | 7.97 (3.1 to 11.9) | 6.99 (2.0 to 11.8) |
| EP-024636 Last Dose | 5.00 (2.8 to 15.0) | 4.88 (0.5 to 8.0) | 6.00 (3.0 to 17.0) | 4.04 (0.0 to 8.3) |
| EP-024594 First Dose | 10.07 (4.1 to 24.1) | 10.23 (4.0 to 12.0) | 11.83 (6.2 to 23.8) | 10.14 (4.9 to 11.9) |
| EP-024594 Last Dose | 8.07 (4.0 to 20.1) | 4.98 (0.0 to 12.0) | 8.00 (0.5 to 17.2) | 5.03 (0.0 to 8.3) |
| EP-024595 First Dose | 23.72 (8.0 to 24.1) | 11.85 (8.0 to 12.2) | 23.75 (11.8 to 24.0) | 11.83 (5.8 to 12.0) |
| EP-024595 Last Dose | 10.90 (3.0 to 22.0) | 5.07 (0.4 to 12.0) | 11.88 (2.8 to 22.3) | 4.04 (0.0 to 9.9) |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| Hours | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 | 14.5 ± 25.4 | 13.8 ± 27.4 | 14.5 ± 31.3 | 13.7 ± 23.5 |
| EP-024636 | 14.5 ± 21.5 | 13.4 ± 21.1 | 14.4 ± 29.8 | 13.5 ± 21.2 |
| EP-024594 | 17.8 ± 18.2 | 16.2 ± 18.5 | 17.5 ± 25.1 | 15.4 ± 17.0 |
| EP-024595 | 28.5 ± 38.2 | 25.5 ± 25.1 | 22.7 ± 15.6 | 23.0 ± 19.4 |
| litres per hour | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| Apparent Systemic Clearance at Steady State (CLss/F) of EDP-938 | 26.9 ± 44.8 | 24.1 ± 28.4 | 21.3 ± 17.6 | 25.0 ± 23.9 |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| 1/hour | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 | 0.05 ± 1.2 | 0.05 ± 1.6 | 0.05 ± 1.5 | 0.05 ± 1.2 |
| EP-024636 | 0.05 ± 1.1 | 0.05 ± 1.2 | 0.05 ± 1.3 | 0.05 ± 1.1 |
| EP-024594 | 0.04 ± 0.7 | 0.04 ± 0.8 | 0.04 ± 1.0 | 0.05 ± 0.8 |
| EP-024595 | 0.03 ± 1.3 | 0.03 ± 0.9 | 0.03 ± 0.5 | 0.03 ± 0.6 |
| litre(s) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss/F) of EDP-938 | 560 ± 42.8 | 476 ± 23.1 | 442 ± 24.1 | 491 ± 28.8 |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| nanograms per milliliter (ng/mL) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 First Dose | — | 679.35 ± 34.5 | — | 565.60 ± 39.5 |
| EDP-938 Last Dose | — | 822 ± 35.2 | — | 525 ± 30.0 |
| EP-024636 First Dose | — | 168 ± 32.1 | — | 149 ± 41.0 |
| EP-024636 Last Dose | — | 228 ± 27.8 | — | 153 ± 28.9 |
| EP-024594 First Dose | — | 75.3 ± 54.4 | — | 68.8 ± 50.8 |
| EP-024594 Last Dose | — | 188 ± 27.4 | — | 133 ± 31.7 |
| EP-024595 First Dose | — | 100 ± 79.6 | — | 99.3 ± 75.4 |
| EP-024595 Last Dose | — | 705 ± 39.1 | — | 515 ± 40.2 |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| nanograms per milliliter (ng/mL) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 First Dose | 404 ± 46.9 | — | 453 ± 31.6 | — |
| EDP-938 Last Dose | 491 ± 56.4 | — | 287 ± 74.0 | — |
| EP-024636 First Dose | 121 ± 43.5 | — | 136 ± 30.5 | — |
| EP-024636 Last Dose | 148 ± 44.4 | — | 88.3 ± 64.8 | — |
| EP-024594 First Dose | 78.8 ± 43.7 | — | 87.8 ± 56.0 | — |
| EP-024594 Last Dose | 127 ± 29.3 | — | 74.5 ± 72.4 | — |
| EP-024595 First Dose | 142 ± 57.5 | — | 163 ± 79.4 | — |
| EP-024595 Last Dose | 461 ± 41.6 | — | 287 ± 93.8 | — |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| ng*hr/mL | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 First Dose | 16730 ± 47.0 | 7540 ± 45.8 | 16420 ± 24.0 | 5970 ± 40.5 |
| EDP-938 Last Dose | 32000 ± 52.9 | 27300 ± 40.8 | 20500 ± 32.1 | 17800 ± 29.0 |
| EP-024636 First Dose | 3800 ± 42.9 | 1490 ± 49.3 | 4080 ± 36.2 | 1300 ± 45.9 |
| EP-024636 Last Dose | 8680 ± 42.9 | 7690 ± 32.8 | 5550 ± 24.1 | 5180 ± 28.8 |
| EP-024594 First Dose | 1610 ± 55.3 | 512 ± 73.1 | 1740 ± 64.2 | 487 ± 51.5 |
| EP-024594 Last Dose | 6880 ± 31.7 | 7160 ± 27.5 | 4320 ± 37.3 | 4990 ± 31.6 |
| EP-024595 First Dose | 2510 ± 72.1 | 540 ± 95.6 | 2420 ± 83.1 | 541 ± 67.1 |
| EP-024595 Last Dose | 29600 ± 40.5 | 36900 ± 38.4 | 19700 ± 77.1 | 25800 ± 46.6 |
The metabolites of EDP-938 that were assessed were EP-024636, EP-024594 and EP-024595.
| ng*hr/mL | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| EDP-938 | 22300 ± 46.5 | 12500 ± 29.7 | 14100 ± 18.5 | 8010 ± 24.9 |
| EP-024636 | 5770 ± 36.1 | 3270 ± 25.2 | 3640 ± 24.5 | 2210 ± 30.8 |
| EP-024594 | 3830 ± 30.6 | 2470 ± 26.1 | 2410 ± 45.4 | 1710 ± 33.8 |
| EP-024595 | 12100 ± 41.9 | 8950 ± 36.7 | 8350 ± 82.0 | 6210 ± 44.3 |
The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable viral load AUC i.e. a low PK AUC and a high viral load AUC indicated a correlation.
| Participants | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC | 0 | 0 | 0 | 0 |
The overall criteria to define correlation was based on identifying a PK AUC associated with a less favorable TSS AUC, i.e. a low PK AUC and a high TSS AUC indicated a correlation.
| Participants | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg |
|---|---|---|---|---|
| Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC | 0 | 0 | 0 | 0 |
Collected over All cause mortality was monitored from enrollment until end of study (Day 28) for the safety analysis population which included all participants who received challenge virus, regardless of whether they received study drug or not. Treatment-emergent serious and other adverse events (AEs) were monitored from Day 2 to Day 28 and only included participants in the safety analysis population who received study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: EDP-938 600 mg | 0/39 (0%) | 0/38 (0%) | 20/38 (52.6%) |
| Part 1: EDP-938 500 mg Then 300 mg | 0/38 (0%) | 0/38 (0%) | 21/38 (55.3%) |
| Part 1: Placebo | 0/38 (0%) | 0/38 (0%) | 21/38 (55.3%) |
| Part 2: EDP-938 600 mg Then 300 mg | 0/21 (0%) | 0/21 (0%) | 8/21 (38.1%) |
| Part 2: EDP-938 400 mg Then 200 mg | 0/21 (0%) | 0/21 (0%) | 10/21 (47.6%) |
| Part 2: Placebo | 0/21 (0%) | 0/21 (0%) | 11/21 (52.4%) |
| Event | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/38 | 1/38 | 3/38 | 1/21 | 3/21 | 0/21 |
| Upper respiratory tract infectionInfections and infestations | 2/38 | 2/38 | 4/38 | 1/21 | 2/21 | 1/21 |
| DizzinessNervous system disorders | 4/38 | 0/38 | 1/38 | 0/21 | 2/21 | 1/21 |
| HeadacheNervous system disorders | 4/38 | 1/38 | 3/38 | 0/21 | 1/21 | 2/21 |
| Viral upper respiratory tract infectionInfections and infestations | 1/38 | 0/38 | 1/38 | 0/21 | 2/21 | 0/21 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/38 | 0/38 | 0/38 | 0/21 | 2/21 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 3/38 | 3/38 | 0/38 | 1/21 | 1/21 | 0/21 |
| Ear painEar and labyrinth disorders | 0/38 | 1/38 | 2/38 | 0/21 | 1/21 | 0/21 |
| Abdominal painGastrointestinal disorders | 0/38 | 2/38 | 1/38 | 0/21 | 0/21 | 1/21 |
| DyspepsiaGastrointestinal disorders | 1/38 | 2/38 | 0/38 | 0/21 | 0/21 | 0/21 |
In Part 1, one participant in the Safety Analysis Set did not receive study treatment and is not included in this baseline analysis population.
| Age, Categorical(Participants) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 38 | 38 | 21 | 21 | 21 | 177 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 13 | 18 | 13 | 10 | 11 | 9 | 74 |
| Male | 25 | 20 | 25 | 11 | 10 | 12 | 103 |
| Race (NIH/OMB)(Participants) | Part 1: EDP-938 600 mg | Part 1: EDP-938 500 mg Then 300 mg | Part 1: Placebo | Part 2: EDP-938 600 mg Then 300 mg | Part 2: EDP-938 400 mg Then 200 mg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 | 1 | 1 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 0 | 1 | 0 | 4 |
| White | 33 | 32 | 31 | 18 | 17 | 19 | 150 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 3 | 2 | 2 | 2 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Sep 2019, 11 months.
Results were first posted in May 2022, 2 years 7 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 11 months is close to that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-938
Respiratory Syncytial Virus Infections →